Literature DB >> 5526612

Blood glucose variations and clinical experience with glibenclamide in diabetes mellitus.

D J O'Sullivan, W F Cashman.   

Abstract

Thirty patients were treated with glibenclamide for periods up to 16 months. The drug is a potent hypoglycaemic agent, and taken in a single daily dose controls blood glucose levels over a 24-hour period in maturity onset diabetes. A definite dose-effect relationship exists, and the drug may be used in doses of 5 to 20 mg. daily. There were no appreciable side-effects or toxic effects during the period of study.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5526612      PMCID: PMC1700211          DOI: 10.1136/bmj.2.5709.572

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  3 in total

1.  [Clinical studies on the effect of a new oral antidiabetic agent Glybenclamide (HB 419)].

Authors:  H Schmitt; H Höhler; H Daweke; K Jahnke
Journal:  Dtsch Med Wochenschr       Date:  1969-04-18       Impact factor: 0.628

2.  [A new highly-active oral antidiabetic].

Authors:  W Aumüller; A Bänder; R Heerdt; K Muth; W Pfaff; F H Schmidt; H Weber; R Weyer
Journal:  Arzneimittelforschung       Date:  1966-12

3.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus.

Authors:  H S Seltzer; E W Allen; A L Herron; M T Brennan
Journal:  J Clin Invest       Date:  1967-03       Impact factor: 14.808

  3 in total
  4 in total

1.  Saskatchewan president says health care too important to be political gambit.

Authors:  C B Fairbairn
Journal:  Can Med Assoc J       Date:  1976-12-04       Impact factor: 8.262

2.  Glibenclamide for diabetes.

Authors: 
Journal:  Br Med J       Date:  1971-02-27

Review 3.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

Review 4.  Glibenclamide: a review.

Authors: 
Journal:  Drugs       Date:  1971       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.